MeSH term
Frequency | Condition_Probility | Animals | 88 | 0.0 |
Aortic Aneurysm/surgery | 2 | 13.0 |
Bioprosthesis/standards | 2 | 15.0 |
Equipment Failure | 2 | 8.0 |
Heart Valve Diseases/pathology/surgery | 2 | 15.0 |
Heart Valve Prosthesis/*standards | 2 | 15.0 |
Humans | 136 | 0.0 |
Postoperative Complications/etiology | 2 | 5.0 |
Prosthesis Design | 2 | 4.0 |
*Stents | 2 | 3.0 |
Swine | 2 | 0.0 |
Cell Line | 44 | 0.0 |
DNA-Binding Proteins/*drug effects/genetics/metabolism | 2 | 50.0 |
Drug Synergism | 6 | 0.0 |
Erythropoietin/*pharmacology | 6 | 5.0 |
*Milk Proteins | 121 | 25.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Serine/metabolism | 6 | 1.0 |
Trans-Activators/*drug effects/genetics/metabolism | 2 | 50.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Transfection | 22 | 0.0 |
*Apolipoproteins | 2 | 6.0 |
Base Sequence | 22 | 0.0 |
Binding Sites | 15 | 0.0 |
Conserved Sequence | 2 | 0.0 |
DNA-Binding Proteins/drug effects/genetics/*metabolism | 2 | 14.0 |
Female | 35 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
*Glycoproteins | 2 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Molecular Sequence Data | 26 | 0.0 |
Mutation | 10 | 0.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
Research Support, Non-U.S. Gov't | 86 | 0.0 |
Response Elements | 4 | 1.0 |
Signal Transduction | 22 | 0.0 |
Trans-Activation (Genetics) | 11 | 0.0 |
Trans-Activators/drug effects/genetics/*metabolism | 2 | 16.0 |
Tumor Cells, Cultured | 25 | 0.0 |
DNA-Binding Proteins/deficiency/genetics/*physiology | 2 | 8.0 |
Disease Progression | 3 | 0.0 |
Mice | 61 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Mice, Transgenic | 8 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Trans-Activators/deficiency/genetics/*physiology | 2 | 13.0 |
Active Transport, Cell Nucleus | 3 | 1.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Cells, Cultured | 25 | 0.0 |
DNA-Binding Proteins/*metabolism | 36 | 1.0 |
Phosphorylation | 50 | 0.0 |
Prolactin/*pharmacology | 7 | 8.0 |
*Promoter Regions (Genetics) | 8 | 0.0 |
Trans-Activators/*metabolism | 35 | 3.0 |
Tyrosine/metabolism | 21 | 1.0 |
src Homology Domains | 2 | 0.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Cell Nucleus/metabolism | 13 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 4 | 1.0 |
Prolactin/*metabolism | 2 | 3.0 |
Trans-Activators/genetics/*physiology | 4 | 4.0 |
Transcription, Genetic | 14 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
Exons | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Hela Cells | 5 | 0.0 |
Introns | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Trans-Activators/*genetics | 8 | 2.0 |
DNA/metabolism | 12 | 0.0 |
DNA-Binding Proteins/analysis/*metabolism | 2 | 10.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Immunoblotting | 6 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Lactation | 2 | 3.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Pregnancy | 7 | 0.0 |
Prolactin/pharmacology | 4 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 47 | 0.0 |
Trans-Activators/analysis/*metabolism | 2 | 25.0 |
Cell Division | 14 | 0.0 |
Cell Line, Transformed | 4 | 0.0 |
DNA-Binding Proteins/genetics/metabolism/*physiology | 3 | 5.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Trans-Activators/genetics/metabolism/*physiology | 3 | 11.0 |
Amino Acid Sequence | 19 | 0.0 |
CHO Cells | 3 | 0.0 |
Cell Division/drug effects | 7 | 0.0 |
Cyclin D1/*genetics | 2 | 3.0 |
DNA-Binding Proteins/*physiology | 5 | 0.0 |
Hamsters | 5 | 0.0 |
Prolactin/*physiology | 2 | 5.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
*Proto-Oncogene Proteins | 21 | 1.0 |
Trans-Activators/*physiology | 7 | 2.0 |
Blotting, Western | 10 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Luciferases/metabolism | 6 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 11 | 1.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Stem Cells/metabolism | 2 | 2.0 |
Time Factors | 11 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 4 | 2.0 |
Growth Hormone/*physiology | 3 | 11.0 |
Signal Transduction/*drug effects | 6 | 1.0 |
Aged | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 15 | 1.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
Male | 17 | 0.0 |
Middle Aged | 6 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Trans-Activators/genetics/*metabolism | 16 | 4.0 |
Mammary Glands, Animal/*metabolism | 3 | 15.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Phenotype | 4 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cytokines/metabolism | 5 | 1.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Down-Regulation | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
*Gene Expression Regulation | 9 | 0.0 |
Interleukin-3/metabolism | 2 | 6.0 |
Plasmids/metabolism | 5 | 0.0 |
Protein Binding | 17 | 0.0 |
Protein Structure, Tertiary | 7 | 0.0 |
Trans-Activators/*genetics/*metabolism | 2 | 5.0 |
*Transcription, Genetic | 5 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
DNA, Complementary | 3 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
T-Lymphocytes/*drug effects/metabolism | 2 | 5.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
COS Cells | 8 | 0.0 |
Enzyme Activation | 9 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
K562 Cells | 3 | 0.0 |
Phosphotyrosine/*metabolism | 2 | 3.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 2 | 0.0 |
*Signal Transduction | 13 | 0.0 |
Trans-Activators/chemistry/*metabolism/*physiology | 2 | 66.0 |
Cattle | 5 | 0.0 |
Receptors, Glucocorticoid/metabolism | 2 | 3.0 |
Sequence Alignment | 4 | 0.0 |
Growth Hormone/*pharmacology | 6 | 8.0 |
Protein Isoforms | 6 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 12 | 1.0 |
Rats | 17 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Signal Transduction/physiology | 5 | 0.0 |
*Repressor Proteins | 4 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Gene Expression Regulation | 8 | 0.0 |
Models, Genetic | 2 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Amino Acid Motifs | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 10 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Interleukin-2/*pharmacology | 6 | 2.0 |
Receptors, Interleukin-2/*genetics | 3 | 11.0 |
Trans-Activators/metabolism | 11 | 1.0 |
Transcription Factors/metabolism | 4 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Mammary Neoplasms, Animal/*metabolism | 2 | 25.0 |
Signal Transduction/*physiology | 6 | 0.0 |
Trans-Activators/chemistry/*metabolism | 6 | 9.0 |
Cell Division/physiology | 2 | 0.0 |
Cell Survival/physiology | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 4 | 0.0 |
Interleukin-2/*metabolism/pharmacology | 2 | 28.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Breast Neoplasms | 2 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
DNA-Binding Proteins/metabolism/*physiology | 3 | 2.0 |
Trans-Activators/metabolism/*physiology | 2 | 3.0 |
Kinetics | 9 | 0.0 |
Genes, Reporter | 4 | 0.0 |
Insulin/*pharmacology | 3 | 1.0 |
Proteins/*genetics | 2 | 0.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
DNA-Binding Proteins/antagonists & inhibitors/metabolism | 2 | 9.0 |
Trans-Activators/antagonists & inhibitors/metabolism | 2 | 10.0 |
Cyclins/*genetics/metabolism | 2 | 4.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Ligands | 4 | 0.0 |
Threonine/*chemistry | 2 | 50.0 |
Apoptosis | 3 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Comparative Study | 3 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 6 | 3.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Binding Sites/genetics | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Protein Binding/drug effects | 3 | 0.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Receptors, Prolactin/metabolism | 2 | 12.0 |
Immune Tolerance | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Growth Hormone/*metabolism | 2 | 3.0 |
Liver/metabolism | 3 | 0.0 |
Models, Biological | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Dimerization | 6 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Receptors, Interleukin-2/*physiology | 2 | 9.0 |
Trans-Activation (Genetics)/*immunology | 2 | 10.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
Protein Conformation | 3 | 0.0 |
Trans-Activators/chemistry/genetics/*metabolism | 2 | 2.0 |
Androstadienes/*pharmacology | 2 | 9.0 |
Epithelial Cells | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
3T3 Cells | 4 | 0.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Phosphotyrosine/analysis | 2 | 3.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Biological Transport | 3 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Molecular Weight | 2 | 0.0 |
Phosphotyrosine/metabolism | 7 | 1.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Receptors, Somatotropin/genetics/*metabolism | 2 | 14.0 |
Substrate Specificity | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Interferon-alpha/*pharmacology | 2 | 1.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Interleukin-15/pharmacology | 3 | 13.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Cyclins/genetics | 2 | 1.0 |
Mutagenesis | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*genetics/*metabolism | 2 | 5.0 |
Trans-Activators/chemistry/*genetics/*metabolism | 2 | 11.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Interleukin-7/pharmacology | 2 | 4.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
Adult | 7 | 0.0 |
Annexin A5/metabolism | 2 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Lymphokines/*pharmacology | 2 | 0.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
DNA/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics/physiology | 2 | 13.0 |
Tyrosine/*metabolism | 3 | 0.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Interleukin-2/*immunology | 2 | 3.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Caseins/genetics | 2 | 18.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Trans-Activators/*genetics/metabolism | 2 | 1.0 |
*Cloning, Molecular | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Prolactin/metabolism | 2 | 3.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Tyrosine/chemistry | 2 | 1.0 |
HL-60 Cells | 2 | 0.0 |
Tretinoin/pharmacology | 2 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Hydrocortisone/*biosynthesis | 2 | 33.0 |
Transduction, Genetic | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Gene Expression Profiling | 2 | 0.0 |
